Live Imaging and Functional Evaluation Core

项目总结-生命周期核心 SEI视觉研究小组在使用鼠标模型方面有着长期的记录 研究眼球的突起和紊乱。这些小鼠模型的体内特征是 使用LIFE核心提供的测试模式进行。这一资源一直是 自1999年作为努西诺维茨实验室的一部分提供，自2009年以来一直是 SEI核心赠款的组成部分。随着使用各种鼠标的项目的增长 菌株和突变体，以及扩大翻译研究项目以修改或拯救 眼科疾病，生命组件技术对于监测广泛的 在活体动物身上做实验。 LIFE核心组件将继续提供广泛的体内功能和 根据研究人员的研究兴趣定制结构测试。《生活》 核心将被用来定义获得性或新的 生成了小鼠突变体，以确认它们是否显示预期的表型、视觉 行为和/或电生理反应。此外，调查人员将继续使用 LIFE CORE在小鼠模型使用前记录疾病的自然历史 用于介入性实验，包括病毒载体、干细胞或 基于药理的。 LIFE董事致力于提供最先进的非侵入性 小鼠眼部疾病模型的成像和功能分析。设备和软件 算法会定期升级。我们最近将Bioptigen SD-OCT更新为 提供更高分辨率的视网膜图像，并添加了新的光学孔来成像前部 啮齿动物的节段。后者是一种新功能，突出了我们对扩展 这一资源与SEI的其他调查人员的相关性。此外，我们还购买了一台新的Celeris 用于视网膜和视觉通路功能评估的电诊断系统 更换老化的定制系统。在接下来的研究期间，我们将扩展成像 通过增加Heidelberg HRA-II用于荧光生物标记物的广域成像和 自发荧光，我们将继续与我们在Doheny Eye Institute的同事合作，我们的 附属眼科医院，为小鼠开发OCT-A。最后，我们将添加行为 用视动反射测试视力和对比敏感度，并开发新的 视网膜变性中视杆细胞和视锥细胞功能的行为范式研究。

PROJECT SUMMARY – LIFE CORE The SEI Vision Research Group has a longstanding track record of using mouse models to study ocular processes and disorders. The in vivo characterization of these mouse models is carried out using the testing modalities provided by the LIFE Core. This resource has been available since 1999 as part of the Nusinowitz Laboratory and, since 2009, has been a component of the SEI Core Grant. With the growth of projects using a wide variety of mouse strains and mutants, and the expansion of translational research projects to modify or rescue ocular disorders, the LIFE component technologies are crucial for monitoring a broad range of experiments in living animals. The LIFE Core component will continue to offer a broad range of in vivo functional and structural testing customized to the needs of the investigator's research interests. The LIFE Core will be used to define the structural and functional phenotypes in acquired or newly generated mouse mutants to confirm whether they display the expected phenotypes, visual behavior and/or electrophysiological responses. In addition, investigators will continue to use the LIFE Core to document the natural history of disease in mouse models before they are used for interventional experiments, including those that are viral vector, stem cell, or pharmacologically based. The LIFE directors are committed to the provision of state-of-the-art non-invasive imaging and functional analysis of mouse models of ocular disease. Equipment and software algorithms are upgraded on a regular basis. We recently updated our Bioptigen sd-OCT to provide higher resolution retinal images and have added new optical bores to image the anterior segment in rodents. The latter is a new capability and highlights our interest in broadening the relevance of this resource to other investigators at SEI. In addition, we acquired a new Celeris Electrodiagnostics System for functional evaluation of the retina and visual pathway that will replace an aging custom-made system. Over the next study period we will expand the imaging capabilities by adding a Heidelberg HRA-II for wide-field imaging of fluorescent biomarkers and autofluorescence, and we will continue to work with our colleagues at Doheny Eye Institute, our affiliated eye hospital, to develop OCT-A for the mouse. Lastly, we will be adding behavioral testing of visual acuity and contrast sensitivity with the optokinetic reflex, and developing new behavioral paradigms to study rod and cone function in retinal degeneration.